AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BDSX · NASDAQ · Medical - Diagnostics & Research

Biodesix

Uses multi-omic testing to address clinical questions in lung disease.

$26.83

After-hours close+0.06 (+0.22%)

At close$26.77(−6.00%)

Something off on this page? Send us feedback.

Profile

Biodesix, Inc.BDSXHealth Care

Lung diagnostic testing for healthcare providers and development services for biopharmaceutical customers generate revenue. A multi-omic approach addresses clinical questions in lung disease, with testing and services performed in Colorado and Kansas.

Blood-based, multi-omic tests address clinical questions in lung disease for healthcare providers. Lung diagnostic testing is one revenue source, alongside development services for biopharmaceutical customers.

Testing and services are performed in Louisville, Colorado, and De Soto, Kansas. The portfolio grew through the Integrated Diagnostics acquisition, including rights to the Nodify XL2 test, and the acquisition of Nodify CDT.

Commercial operations pair diagnostic testing with services for biopharmaceutical companies. The business focuses on clinical care and outcomes through multi-omic diagnostics, with testing and services performed in its Louisville and De Soto laboratories.

Company facts

CEOScott Hutton

ListedOct 28, 2020

ExchangeNASDAQ

HeadquartersLouisville, CO

CountryUnited States

Employees334

CIK0001439725

ISINUS09075X2071

Key statistics

Market cap$218.4M

EPS (ttm)−$3.17

P/E (ttm)−8.46

ROE-788.2%

P/B30.21

P/S2.12

Dividend yield—

Beta1.00vs XLV 0.53

Year to date +314% · Average volume (30d) 112.9K

Analysts

Price target, next 12 months$32.00+19.3%Median of 8 analysts · vs the Aug 28 close

ConsensusBuy7 of 8 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $26.83

High$35.00+30.5%

Median$32.00+19.3%

Low$26.00−3.1%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Aug 10, 2026	Canaccord Genuity	Reiterate		Buy	$27	$35
Jun 24, 2026	Roth Capital	Initiate		Buy		$32
Jun 18, 2026	Canaccord Genuity	Reiterate		Buy	$20	$27
Jun 15, 2026	H.C. Wainwright	Target				$26
Feb 27, 2026	William Blair	Upgrade	Market Perform	Outperform

Earnings

EPS

Estimate−$0.74

ReportedDue Nov 2, 2026

Revenue

Estimate$27.6M

ReportedDue Nov 2, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.90	−$0.71	+21.3%	$26.0M	$26.9M	+3.2%	−2.99%
May 4, 2026Q1 FY26	−$1.26	−$0.81	+35.7%	$23.1M	$25.6M	+10.5%	+32.56%
Feb 26, 2026Q4 FY25	−$1.05	−$0.49	+53.3%	$25.7M	$28.8M	+11.8%	+7.81%
Nov 3, 2025Q3 FY25	−$1.60	−$1.16	+27.5%	$26.3M	$21.8M	−17.1%	+19.87%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$18.0M	$20.0M	$21.8M	$28.8M	$25.6M	$26.9M
Gross profit	$14.3M	$16.0M	$17.7M	$23.9M	$21.4M	$22.0M
Operating income	−$9.1M	−$9.7M	−$7.0M	−$2.0M	−$6.2M	−$5.4M
Net income	−$11.1M	−$11.5M	−$8.7M	−$4.0M	−$7.8M	−$7.3M
Diluted EPS	−$1.51	−$1.56	−$1.16	−$0.49	−$0.81	−$0.71
Gross margin	79.4%	79.9%	81.1%	83.0%	83.5%	82.1%
Operating margin	-50.5%	-48.4%	-32.4%	-6.8%	-24.2%	-20.1%

Fiscal years (4-quarter sums)FY21 $54.5M · FY22 $38.2M · FY23 $49.1M · FY24 $71.3M · FY25 $88.5M

Revenue by product · Q2 FY26

Diagnostic Tests$25.3M · 94%

Development Services$1.5M · 6%

Balance sheet, Jun 30, 2026Cash & short-term investments $30.0M · Total debt $71.8M · Total assets $95.3M · Shareholders' equity $9.1M

Dividends

No dividends on record.

Ownership

Institutions 44.41%3.62M sharesInsiders 10.08%820.3K sharesOther 45.51%3.70M shares

Shares outstanding 8.14M · Float 4.66M · 57.2% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Aigh Capital Management LLC	758.3K	9.32%	13F	Apr 30, 2026
Orin Hirschman	758.3K	7.70%	13G	Apr 28, 2026
Jack W. Schuler · 10 percent owner, other: Emeritus Director	555.8K	6.83%	Form 4	Aug 13, 2026
Soleus Capital Master Fund, L.P.	525.2K	5.10%	13G	Jun 18, 2026
Telemark Asset Management, LLC	489.8K	6.02%	13F	May 12, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 12, 2026	Jack W. Schuler	10 percent owner, other: Emeritus Director	+15,000	$24.47
Aug 11, 2026	Jack W. Schuler	10 percent owner, other: Emeritus Director	+13,700	$24.01
Aug 10, 2026	Jack W. Schuler	10 percent owner, other: Emeritus Director	+13,900	$24.25
Feb 23, 2026	Scott Hutton	director, officer: President & CEO	−1,490	$12.78
Feb 23, 2026	Chris Vazquez	officer: Chief Accounting Officer	−211	$12.78